Erasca, Inc.
ERASNasdaq
$19.17
↑ +0.8%Jul 17 close · end-of-day
Price
1Y↑ +1231.3%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$5.8B
Enterprise Value
$5.6B
P/E
—
P/S
—
P/B
14.8
EV/EBITDA
—
PEG
—
FCF Yield
-1.6%
Dividend Yield
—
Revenue (TTM)
—
Net Income (TTM)
-$277.0M
Free Cash Flow (TTM)
-$91.4M
Gross Margin
—
Operating Margin
—
Net Margin
—
ROE
-70.4%
ROIC
-154.7%
Debt / Equity
—
Net Cash
$243.8M
Return 1Y
+1186.6%
Company profile
Erasca, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead candidates include ERAS-007, an oral inhibitor of ERK1/2 for the treatment of non-small cell lung cancer, colorectal cancer, and acute myeloid leukemia.
- CEO
- Jonathan E. Lim
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 120
- Headquarters
- California
- Website
- erasca.com
Management & directors
- Garner EbunGeneral Counsel & Corp. Sec.
- Morris ShannonChief Medical Officer
- Chacko David M.CFO and CBO
Roles derived from SEC Form 4 filings.
Earnings
ERAS Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue——
Diluted EPS-$0.60↑ +445.5%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$109.3M | -$124.9M | -$247.4M | -$141.5M | -$179.6M | -$140.9M |
| Net income | -$101.7M | -$122.8M | -$242.8M | -$125.0M | -$161.7M | -$124.5M |
| Diluted EPS | — | -$1.85 | -$1.99 | -$0.83 | -$0.69 | -$0.44 |
| Operating cash flow | -$32.7M | -$79.6M | -$103.3M | -$101.2M | -$109.4M | -$95.5M |
| Free cash flow | -$33.6M | -$90.8M | -$117.8M | -$103.0M | -$109.5M | -$95.6M |
| Gross margin | — | — | — | — | — | — |
| Operating margin | — | — | — | — | — | — |
| Net margin | — | — | — | — | — | — |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | -$67.8M | -$37.2M | -$35.7M | -$35.6M | -$38.1M | -$34.5M | -$32.6M | -$187.9M |
| Net income | -$63.2M | -$31.2M | -$32.2M | -$31.0M | -$33.9M | -$30.6M | -$29.1M | -$183.4M |
| Diluted EPS | -$0.29 | -$0.11 | -$0.06 | -$0.11 | -$0.12 | -$0.11 | -$0.10 | -$0.60 |
| Operating cash flow | -$29.2M | -$22.4M | -$24.6M | -$31.6M | -$20.5M | -$21.7M | -$21.7M | -$27.4M |
| Free cash flow | -$29.2M | -$22.4M | -$24.6M | -$31.6M | -$20.6M | -$21.7M | -$21.7M | -$27.4M |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | — | — | — | — | — | — | — | — |
| Net margin | — | — | — | — | — | — | — | — |
Company news
Jul 16, 2026
Jul 15, 2026
- 5d agoErasca Announces Closing of Upsized Public Offering of Common Stock, Including Full Exercise of Underwriters’ Option to Purchase Additional Sharesfinance.yahoo.com
- 5d agoErasca (ERAS) Trial Update Draws Fresh Focus, Is The Valuation Already Full?finance.yahoo.com
- 5d agoErasca (ERAS) Is Up 6.2% After Advancing ERAS-0015 Toward Registration Trials In RAS Cancersfinance.yahoo.com
Jul 14, 2026
Jul 13, 2026
Jul 2, 2026
- 18d agoRobinhood and 4 More Stocks That Were Just Added to This Firm’s ‘Top Picks’ Listfinance.yahoo.com
- 18d agoTango Therapeutics Rides a New Precision Oncology Trend in 2026finance.yahoo.com
- 18d agoIs TNGX Stock Still Worth Buying After Its Huge Rally in 2026?finance.yahoo.com
- 18d agoTNGX Stock Outlook Hinges on Vopimetostat and Key 2026 Catalystsfinance.yahoo.com
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-04-01 | Garner Ebun· Chief Legal Officer | Sale | 80,000 | $16.40 | $1.3M | filing |
| 2026-04-01 | Garner Ebun· Chief Legal Officer | Option exercise | 80,000 | $1.70 | $136,000.00 | filing |
| 2026-03-04 | Morris Shannon· Chief Medical Officer | Sale | 20,000 | $15.04 | $300,760.00 | filing |
| 2026-03-04 | Morris Shannon· Chief Medical Officer | Option exercise | 20,000 | $1.70 | $34,000.00 | filing |
| 2026-01-07 | Garner Ebun· General Counsel & Corp. Sec. | Sale | 120,000 | $5.59 | $670,812.00 | filing |
| 2026-01-07 | Garner Ebun· General Counsel & Corp. Sec. | Option exercise | 120,000 | $1.70 | $204,000.00 | filing |
| 2025-12-15 | Chacko David M.· CFO and CBO | J | 17,793 | $1.19 | $21,250.18 | filing |
| 2025-12-15 | Garner Ebun· General Counsel & Corp. Sec. | Award | 3,902 | $1.19 | $4,660.16 | filing |
Latest 8 transactions.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.